semaglutide injection germantown in Memphis SpaDerma | Semaglutide | Tirzepatide

Outcomes Primary and Secondary Outcome Patients in the semaglutide study arm experienced a significantly lower rate of the primary outcome (cardiovascular composite end-point) (6.5% vs 8.0%, HR 0.80 (95% CI 0.72-0.90) No significant difference in rates of cardiac death (HR 0.85, 95% CI 0.71-1.01) however significantly lower rates of heart failure (HR 0.82, 95% CI 0.71-0.96) and all-cause mortality (HR 0.81, 95% CI 0.71-0.93) Adverse Events Rates and types of adverse events were fairly similar between control and intervention groups Permanent premature discontinuation of semaglutide or placebo occurred in 2351 patients (26.7%) in the semaglutide group and 2078 (23.6%) in the placebo group In obese and overweight patients with cardiovascular comorbidities but without diabetes, treatment with weekly semaglutide was superior to placebo in reducing the incidence of death from cardiovascular causes, nonfatal myocardial infarction, or nonfatal stroke at a mean follow-up of 39.8 months

Low-density lipoprotein cholesterol (LDL-C) reductions are more modest, generally in the range of 2-10%, though some patients experience more substantial decreases

Konrad P, Chojnacki J, Kaczka A, Pawowicz M, Rudnicki C, Chojnacki C

See: References 1 Di Cesare M, Perel P, Taylor S, et al

An increase in red blood cell distribution width from baseline predicts mortality in patients with severe sepsis or septic shock